Results of Low-Dose Cytosine Arabinoside and Aggressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes

  • C. Aul
  • W. Schneider
Conference paper


As known from recent studies [7, 8], advanced myelodysplastic syndromes (MDS) are characterized by a poor prognosis. Within 2 years of diagnosis most patients die of infections or hemorrhagic complications related to bone marrow failure or development of acute leukemia. Despite a number of clinical trials no generally accepted form of treatment exists for this syndrome [2]. Based on earlier reports, aggressive antileukemic regimens have been regarded as ineffective or even dangerous because of the risk of severe and prolonged aplasia [1]. During the past decade, many authors have concentrated on the use of low-dose cytosine arabinoside (ara-C), but published data are difficult to compare due to varying doses and schedules in the administration of ara-C [6].


Toxicity Leukemia Oncol Thrombocytopenia Stein 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Armitage JO, Dick FR, Needleman SW, Burns CP (1981) Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65: 601–605PubMedGoogle Scholar
  2. 2.
    Aul C, Heyll A, Gattermann N, Schneider W (1987) Therapie der myelodysplastischen Syndrome. Dtsch Med Wochenschr 112: 309–313PubMedCrossRefGoogle Scholar
  3. 3.
    Barlogie B, Johnston DA, Keating M, Spitzer G, Hittelman WN, Nishioki K, Freireich EJ (1984) Evolution of oligoleukemia. Cancer 53: 2115–2124PubMedCrossRefGoogle Scholar
  4. 4.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  5. 5.
    Büchner Th, Urbanitz D, Brücher H, Heinecke A, Hiddemann W, Rühl H, Schulte H, Wendt F (1984) Chemotherapie der akuten myeloischen Leukämie des Erwachsenen. In: Büchner Th, Urbanitz D, Van De Loo J (eds) Therapie der akuten Leukämien. Springer, Berlin Heidelberg New York, pp 59–71Google Scholar
  6. 6.
    Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 12: 1857–1864Google Scholar
  7. 7.
    Foucar K, Langdon RM, Armitage JO, Olson DB, Carroll TJ (1985) Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 56: 553–561PubMedCrossRefGoogle Scholar
  8. 8.
    Kerkhofs H, Hermans J, Haak HL, Leeksma CHW (1987) Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65: 73–81PubMedCrossRefGoogle Scholar
  9. 9.
    Lazzarino M, Mona E, Inverardi D, Alessandrino EP, Castelli G, Bernasconi P, Castagnola C, Bernasconi C (1986) Combined etoposide (VP-16) and cytarabine (ara-C) for acute myelogenous le ukemias (AML) evolving from myelodysplastic syndromes (MDS) or secondary to treatment for malignant diseases ( MD ). Proc Am Soc Clin Oncol 5: 161Google Scholar
  10. 10.
    Liliemark JO, Gahrton G, Paul CY, Peterson CO (1987) Ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia. Semin Oncol 14: 167–171PubMedGoogle Scholar
  11. 11.
    Preisler HD, Early AP, Raza A, Vlahides G, Marinello MJ, Stein AM, Browman G (1983) Therapy of secondary acute nonlymphocytic leukemia with cytarabine. N Engl J Med 308: 21–23PubMedCrossRefGoogle Scholar
  12. 12.
    Spriggs D, Griffin J, Wisch J, Kufe D (1985) Clinical pharmacology of low-dose cytosine arabinoside. Blood 65: 1087–1089PubMedGoogle Scholar
  13. 13.
    Tricot G, Boogaerts MA (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63: 477–483PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • C. Aul
  • W. Schneider

There are no affiliations available

Personalised recommendations